DNA甲基化在皮肤恶性肿瘤中差异表达与临床意义

doi:10.13418/j.issn.1001-165x.2025.4.21

PDF(1544 KB)

中国临床解剖学杂志 ›› 2025, Vol. 43 ›› Issue (4) : 486-490. DOI: 10.13418/j.issn.1001-165x.2025.4.21

综述

DNA甲基化在皮肤恶性肿瘤中差异表达与临床意义

唐亚平，黄逸骁，王鲁梅，陈英华*

作者信息 +

Differential expression and clinical significance of DNA methylation in skin cancer

Tang Yaping, Huang Yixiao, Wang Lumei, Chen Yinghua*

Author information +

文章历史 +

摘要

近年来，表观遗传学研究发现，DNA甲基化作为关键调控机制影响肿瘤相关基因的表达，参与皮肤癌的发生、发展和转移。本文聚焦于黑色素瘤、基底细胞癌和鳞状细胞癌，总结了CLDN11、MGMT、PTCH1、ID4等基因的甲基化状态与三种皮肤癌进展的关联，探讨了甲基化检测技术在临床诊断和治疗中的应用潜力。文章也对基于DNA甲基化的新型治疗策略进行了展望。明确关键甲基化基因及其作用机制，为皮肤癌的早期筛查、分子分型和靶向治疗提供理论依据。

Abstract

Recent epigenetic studies demonstrate that DNA methylationa key regulatory mechanism modulates tumor related gene expression and drives the development, progression, and metastasis of skin cancer. This review summarizes evidence on how methylation levels of key genes (CLDN11, MGMT, PTCH1, ID4) drive progression in melanoma, basal cell carcinoma (BCC), and cutaneous squamous cell carcinoma (cSCC) the three predominant skin malignancies-and evaluates the clinical utility of methylation detection techniques for diagnosis and treatment. The article also discusses emerging therapeutic strategies targeting DNA methylation and elucidates critical methylated genes with their underlying mechanisms, providing a theoretical foundation for early detection, molecular subtyping, and targeted therapy of skin cancer.

导出引用

唐亚平, 黄逸骁, 王鲁梅, 陈英华. DNA甲基化在皮肤恶性肿瘤中差异表达与临床意义[J]. 中国临床解剖学杂志. 2025, 43(4): 486-490 https://doi.org/10.13418/j.issn.1001-165x.2025.4.21

Tang Yaping, Huang Yixiao, Wang Lumei, Chen Yinghua. Differential expression and clinical significance of DNA methylation in skin cancer[J]. Chinese Journal of Clinical Anatomy. 2025, 43(4): 486-490 https://doi.org/10.13418/j.issn.1001-165x.2025.4.21

中图分类号： R361.3

参考文献

[1] Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer[J]. Trends Genet, 2021, 37(11): 1012-1027. DOI:10.1016/j.tig.2021.05.002.
[2] Patani H, Rushton MD, Higham J, et al. Transition to naïve human pluripotency mirrors pan-cancer DNA hypermethylation[J].Nat Commun,2020,11:3671. DOI:10.1038/s41467-020-17269-3.
[3] He J, He H, Qi Y, et al . Application of epigenetics in dermatological research and skin management[J].J Cosmet Dermatol,2022,21(5):1920-1930. DOI:10.1111/jocd.14355.
[4] Chen Z, Zhang Y . Role of Mammalian DNA Methyltransferases in Development[J]. Annu Rev Biochem, 2020, 89: 135-158. DOI:10.1146/annurev-biochem-103019-102815.
[5] Herman JG, Baylin SB . Gene silencing in cancer in association with promoter hypermethylation[J]. N Engl J Med, 2003, 349(21): 2042-2054. DOI:10.1056/NEJMra023075.
[6] Ressler JM, Tomasich E, Hatziioannou T, et al . DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma[J]. Target Oncol, 2024, 19(2): 263-275. DOI:10.1007/s11523-024-01041-4.
[7] Gao L, van den Hurk K, Moerkerk PTM, et al . Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy[J]. J Invest Dermatol, 2014, 134(12): 2957-2966. DOI:10.1038/jid.2014.270.
[8] Busch C, Geisler J, Lillehaug JR, et al . MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC[J]. Eur J Cancer, 2010, 46(11): 2127-2133. DOI:10.1016/j.ejca.2010.04.023.
[9] Mori T, O’Day SJ, Umetani N, et al . Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy[J]. J Clin Oncol, 2005, 23(36): 9351-9358. DOI:10.1200/JCO.2005.02.9876.
[10]Spugnardi M, Tommasi S, Dammann R, et al. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma[J]. Cancer Res, 2003, 63(7): 1639-1643. PMID:12670917.
[11]Pabalan N, Kunjantarachot A, Ruangpratheep C, et al . Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis[J]. Gynecol Oncol, 2017, 146(3): 603-608. DOI:10.1016/j.ygyno.2017.06.017.
[12]Meevassana J, Varophas S, Prabsattru P, et al . 5-Methylcytosine immunohistochemistry for predicting cutaneous melanoma prognosis[J]. Sci Rep, 2024, 14(1): 7554. DOI:10.1038/s41598-024-58011-z.
[13]Tellez CS, Shen L, Estécio MRH, et al . CpG island methylation profiling in human melanoma cell lines[J].Melanoma Res,2009,19(3):146-155. DOI:10.1097/cmr.0b013e32832b274e.
[14]Gillespie AM, Coleman RE . The potential of melanoma antigen expression in cancer therapy[J]. Cancer Treat Rev, 1999, 25(4): 219-227. DOI:10.1053/ctrv.1999.0126.
[15]Kuriyama Y, Shimizu A, Kanai S, et al . Expression of long interspersed nuclear elements-1 as a surrogate marker for global genomic hypomethylation of malignant skin tumors[J]. J Dermatol Sci, 2020, 99(3): 213-215. DOI:10.1016/j.jdermsci.2020.07.008.
[16]Tonella L, Pala V, Ponti R, et al . Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications[J]. Int J Mol Sci, 2021, 22(9). DOI:10.3390/ijms22094561.
[17]Cheng PF, Shakhova O, Widmer DS, et al . Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma[J]. Genome Biol, 2015, 16(1): 42. DOI:10.1186/s13059-015-0594-4.
[18]Seidl-Philipp M, Frischhut N, Höllweger N, et al . Known and new facts on basal cell carcinoma[J]. J Dtsch Dermatol Ges, 2021, 19(7): 1021-1041. DOI:10.1111/ddg.14580.
[19]Brinkhuizen T, van den Hurk K, Winnepenninckx VJL, et al . Epigenetic changes in Basal Cell Carcinoma affect SHH and WNT signaling components[J]. PloS One, 2012, 7(12): e51710. DOI:10.1371/journal.pone.0051710.
[20]Chiang A, Tan CZ, Kuonen F, et al . Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma[J]. J Invest Dermatol, 2019,139(11):2263-2271.e5. DOI:10.1016/j.jid.2019.03. 1163.
[21]Athar M, Li C, Kim AL, et al . Sonic hedgehog signaling in Basal cell nevus syndrome[J]. Cancer Res, 2014, 74(18): 4967-4975. DOI:10.1158/0008-5472.CAN-14-1666.
[22]Epstein EH . Basal cell carcinomas: attack of the hedgehog[J]. Nat Rev Cancer, 2008, 8(10): 743-754. DOI:10.1038/nrc2503.
[23]Heitzer E, Bambach I, Dandachi N, et al . PTCH promoter methylation at low level in sporadic basal cell carcinoma analysed by three different approaches[J]. Exp Dermatol, 2010, 19(10): 926-928. DOI:10.1111/j.1600-0625.2010.01120.x.
[24]Wu W, Zhang J, Yang H, et al . Examination of AKAP12 promoter methylation in skin cancer using methylation-sensitive high-resolution melting analysis[J]. Clin Exp Dermatol, 2011, 36(4): 381-385. DOI:10.1111/j.1365-2230.2010.03968.x.
[25]Wu X, Wu T, Li K, et al. The Mechanism and Influence of AKAP12 in Different Cancers[J]. Biomed Environ Sci, 2018, 31(12): 927-932. DOI:10.3967/bes2018.127.
[26]Bucko PJ, Scott JD. Drugs That Regulate Local Cell Signaling: AKAP Targeting as a Therapeutic Option[J]. Annu Rev Pharmacol Toxicol, 2021, 61: 361-379. DOI:10.1146/annurev-pharmtox-022420-112134.
[27]Lodygin D, Yazdi AS, Sander CA . Analysis of 14-3-3sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma[J]. Oncogene, 2003, 22(35): 5519-5524. DOI:10.1038/sj.onc.1206854.
[28]Darr OA, Colacino JA, Tang AL, et al . Epigenetic alterations in metastatic cutaneous carcinoma[J]. Head Neck, 2015, 37(7): 994-1001. DOI:10.1002/hed.23701.
[29]Li L, Li F, Xia Y, et al . UVB induces cutaneous squamous cell carcinoma progression by de novo ID4 methylation via methylation regulating enzymes[J]. EBioMedicine, 2020, 57: 102835. DOI:10.1016/j.ebiom. 2020.102835.
[30]Ko EK, Capell BC. Methyltransferases in the Pathogenesis of Keratinocyte Cancers[J]. Cancers, 2021, 13(14): 3402. DOI:10.3390/cancers13143402.
[31]Zhao H, Ming T, Tang S, et al . Wnt signaling in colorectal cancer: pathogenic role and therapeutic target[J]. Mol Cancer, 2022, 21(1): 144. DOI:10.1186/s12943-022-01616-7.
[32]Lang CMR, Chan CK, Veltri A, et al . Wnt Signaling Pathways in Keratinocyte Carcinomas[J]. Cancers, 2019, 11(9): 1216. DOI:10.3390/cancers11091216.
[33]Murao K, Kubo Y, Ohtani N , et al. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways: Epigenetic abnormalities in cutaneous SCCs[J]. Br J Dermatol, 2006, 155(5): 999-1005. DOI:10.1111/j.1365-2133. 2006. 07487.x.
[34]Sharma P, Chinaranagari S, Patel D, et al . Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer[J]. Cancer Med, 2012, 1(2): 176-186. DOI:10.1002/cam4.16.
[35]Pan Y, Song Y, Cheng L, et al . Analysis of methylation-driven genes for predicting the prognosis of patients with head and neck squamous cell carcinoma[J]. J Cell Biochem, 2019, 120(12): 19482-19495. DOI:10.1002/jcb.29252.
[36]Venza M, Visalli M, Catalano T, et al . DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients[J]. Hum Pathol, 2017, 60: 137-146. DOI:10.1016/j.humpath.2016.10.018.